The paper presents several critical issues that may justify an erratum or even retraction. The claim that Lucidin outperforms FDA-approved Lapatinib is based solely on computational studies, lacking in vitro or in vivo validation, rendering the conclusion highly speculative. Additionally, inconsistencies in docking scores and molecular dynamics results suggest potential data manipulation or selective reporting to favor Lucidin. I strongly recommend that the authors thoroughly reassess these issues to enhance the study’s methodological rigor and ensure greater transparency, reliability, and scientific validity.
